The upregulation of LINC00460 resulted in a markedly reduced overall response rate to osimertinib; high LINC00460 expression in the primary tumor site and plasma of patients with EGFR-mutant NSCLC following osimertinib therapy is indicative of reduced PFS and OS. This evidence concerns the gene LINC00460 and non-small cell lung carcinoma.